JP2023166406A5 - - Google Patents

Download PDF

Info

Publication number
JP2023166406A5
JP2023166406A5 JP2023131860A JP2023131860A JP2023166406A5 JP 2023166406 A5 JP2023166406 A5 JP 2023166406A5 JP 2023131860 A JP2023131860 A JP 2023131860A JP 2023131860 A JP2023131860 A JP 2023131860A JP 2023166406 A5 JP2023166406 A5 JP 2023166406A5
Authority
JP
Japan
Prior art keywords
demand
hae
attack
treatment
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023131860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023166406A (ja
JP7688078B2 (ja
Filing date
Publication date
Priority claimed from GBGB1910116.1A external-priority patent/GB201910116D0/en
Application filed filed Critical
Publication of JP2023166406A publication Critical patent/JP2023166406A/ja
Publication of JP2023166406A5 publication Critical patent/JP2023166406A5/ja
Priority to JP2025084646A priority Critical patent/JP2025124716A/ja
Application granted granted Critical
Publication of JP7688078B2 publication Critical patent/JP7688078B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023131860A 2019-06-14 2023-08-14 遺伝性血管性浮腫の治療 Active JP7688078B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025084646A JP2025124716A (ja) 2019-06-14 2025-05-21 遺伝性血管性浮腫の治療

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
US62/861,725 2019-06-14
GB1910116.1 2019-07-15
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (en) 2019-06-14 2020-06-15 Treatments of hereditary angioedema
JP2021571931A JP7356518B2 (ja) 2019-06-14 2020-06-15 遺伝性血管性浮腫の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021571931A Division JP7356518B2 (ja) 2019-06-14 2020-06-15 遺伝性血管性浮腫の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025084646A Division JP2025124716A (ja) 2019-06-14 2025-05-21 遺伝性血管性浮腫の治療

Publications (3)

Publication Number Publication Date
JP2023166406A JP2023166406A (ja) 2023-11-21
JP2023166406A5 true JP2023166406A5 (https=) 2024-04-23
JP7688078B2 JP7688078B2 (ja) 2025-06-03

Family

ID=67700145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021571931A Active JP7356518B2 (ja) 2019-06-14 2020-06-15 遺伝性血管性浮腫の治療
JP2023131860A Active JP7688078B2 (ja) 2019-06-14 2023-08-14 遺伝性血管性浮腫の治療
JP2025084646A Pending JP2025124716A (ja) 2019-06-14 2025-05-21 遺伝性血管性浮腫の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021571931A Active JP7356518B2 (ja) 2019-06-14 2020-06-15 遺伝性血管性浮腫の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025084646A Pending JP2025124716A (ja) 2019-06-14 2025-05-21 遺伝性血管性浮腫の治療

Country Status (34)

Country Link
US (1) US20220218680A1 (https=)
EP (2) EP4282474A3 (https=)
JP (3) JP7356518B2 (https=)
KR (1) KR102748728B1 (https=)
CN (1) CN114126612A (https=)
AR (1) AR119158A1 (https=)
AU (1) AU2020293614B2 (https=)
BR (1) BR112021024664A2 (https=)
CA (1) CA3142218A1 (https=)
CL (2) CL2021003244A1 (https=)
DK (1) DK3982960T3 (https=)
EA (1) EA202193019A1 (https=)
ES (1) ES2956471T3 (https=)
FI (1) FI3982960T3 (https=)
GB (1) GB201910116D0 (https=)
HR (1) HRP20230696T1 (https=)
HU (1) HUE063163T2 (https=)
IL (1) IL288615A (https=)
LT (1) LT3982960T (https=)
MA (1) MA56187B1 (https=)
MD (1) MD3982960T2 (https=)
MX (1) MX2021014557A (https=)
MY (1) MY205687A (https=)
PH (1) PH12021552966A1 (https=)
PL (1) PL3982960T3 (https=)
PT (1) PT3982960T (https=)
RS (1) RS64412B1 (https=)
SG (1) SG11202113304YA (https=)
SI (1) SI3982960T1 (https=)
SM (1) SMT202300261T1 (https=)
TW (1) TW202112370A (https=)
UA (1) UA129869C2 (https=)
WO (1) WO2020249977A1 (https=)
ZA (1) ZA202110685B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20230381162A1 (en) * 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) * 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2026003532A1 (en) 2024-06-28 2026-01-02 Kalvista Pharmaceuticals Limited Sebetralstat for the treatment of anxiety associated with hereditary angioedema

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
US20130210809A1 (en) 2010-07-14 2013-08-15 Christelle Boléa Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
MY174018A (en) 2013-05-23 2020-03-04 Kalvista Pharmaceuticals Ltd Heterocyclic derivates
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Similar Documents

Publication Publication Date Title
JP2023166406A5 (https=)
JP2023002662A5 (https=)
JP2025142338A5 (https=)
JP2023088944A5 (https=)
JP2022191257A5 (https=)
JP2018507914A5 (https=)
RU2005135016A (ru) Производные хинолина в качестве ингибиторов фосфодиэстеразы
JP2010502612A5 (https=)
JP2009514874A5 (https=)
JPWO2023054732A5 (https=)
JPWO2023195530A5 (https=)
JPWO2023054292A5 (https=)
RU2006141647A (ru) Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
JP2013518061A5 (https=)
JP2017508737A5 (https=)
WO2018163119A1 (en) 1-piperidinepropionic acid for treating a fibrosing disease
JPWO2020163268A5 (https=)
US9084769B2 (en) Compositions comprising non steroidal anti-inflammatory drugs and methods for use thereof
JPWO2020234782A5 (https=)
CN115884770A (zh) 治疗冠状病毒感染的联用药物及治疗方法
JPWO2022101395A5 (https=)
JP2023518430A (ja) 感染症の治療におけるブシラミンの使用
FI3941466T3 (fi) Vafidemstat epävakaan persoonallisuushäiriön ei-aggressiivisen oireiden hoitoon
JPWO2023146974A5 (https=)
JPH08268884A (ja) 敗血病性ショックの治療に有用な医薬組成物ならびに解熱および抗炎症医薬組成物を調製するための6,7−置換−2−アミノテトラリンの使用